NBCA/X
May 8, 2026, 06:03
Risk-Stratified HRT Use Following VTE – NBCA
NBCA shared a post on X:
“The blanket ‘no HRT after VTE’ approach is being challenged — and Dr. Cromwell is leading that conversation.
Her focus: which patient, which formulation, which risk level.
Route matters — transdermal > oral.
Thrombophilia and provocation status are critical.
Progestogen choice matters.
Hematology plus gynecology must collaborate.
Join Dr. Cromwell at NBCA’s May PEP Talk: Women and Blood Clots.
May 12 | 7 PM ET.”
Stay updated with Hemostasis Today.
-
May 8, 2026, 16:27Tanmay Banerjee: Laboratory Error Safety in Hematology Testing
-
May 8, 2026, 16:26Nadishani Ratnayake: Supporting Safer Anticoagulation Care With Digital Tools
-
May 8, 2026, 16:15Jim Hoffman: Thrombomodulin as a Key Regulator of Coagulation and Inflammation
-
May 8, 2026, 16:09Panagiotis Christoforou: Honoured to Receive the ASH Clinical News Reader Response Prize
-
May 8, 2026, 14:59Pat Garcia-Gonzalez: Webinar on 25 Years of Targeted Therapy for CML by The Max Foundation
-
May 8, 2026, 14:58Angel Augusto Pérez Calatayud: A New Chapter in Advancing Patient Blood Management Worldwide with IFPBM
-
May 8, 2026, 14:57Omid Seidizadeh: Next-Generation Sequencing in von Willebrand Disease at WFH 2026
-
May 8, 2026, 14:53Smitirupa Mishra: Deep Insights Into Neutrophil Morphology
-
May 8, 2026, 14:52Wolfgang Miesbach: Hidden Proteins Discovered in the Human Genome